Clinical Trial

LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma

Name: LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma — clinical trial record (NCT06888752)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

A prospective, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-M61SQ in patients with relapsed/refractory multiple myeloma.

Trial Details

NCT Number	NCT06888752
Lead Sponsor	First Affiliated Hospital of Wenzhou Medical University Collaborators: Beijing Boren Hospital, First People's Hospital of Hangzhou
Conditions	Relapsed/Refractory Multiple Myeloma
Enrollment	35 participants
Start Date	2025-03-20
Primary Completion	2030-06-30 (estimated)
Study Completion	2030-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-03-21